COLUMBIA, S.C., March 17, 2016 /PRNewswire/ -- BDI Pharma, Inc. announced today the launch of its Drug Supply Chain Security Act (DSCSA) compliant solution with partner TraceLink. This new service provides customers a one-stop solution for accessing all T3 compliance data from BDI Pharma (transaction information, transaction history and transaction statements) in one central repository that will be retained for a minimum of six years, as is required by the DSCSA.
"Providing a user-friendly electronic solution for accessing and retaining transaction data assists our partners with achieving their compliance requirements," stated Rich Gaton, co-founder and president of BDI Pharma, Inc. "In maintaining our focus on improving the quality and safety of the supply chain, we also wanted to invest in a solution that prepares us to integrate electronically with our trading partners to meet their upcoming DSCSA requirements, as well."
Partners of BDI Pharma wishing to gain access to the TraceLink portal can click here to begin the process.
About BDI Pharma, Inc.
BDI Pharma is the nation's fastest growing, privately-held distributor of specialty pharmaceutical products. With more than two decades of expertise in the industry, the company consistently redefines niche distribution — providing commercialization solutions beyond those of the traditional wholesaler. Through an offering that includes innovative supply chain solutions, reimbursement assistance, specialized product knowledge, 24/7 emergency availability and urgent-need delivery capabilities, BDI Pharma serves as a true ally to both pharmaceutical manufacturers and healthcare providers. The product portfolio includes IVIG, branded and generic specialty pharmaceuticals, chemotherapy, vaccines, albumin, coagulation factors, high-titer or "hyper" immune globulins and other specialty products for rare diseases. BDI Pharma is recognized as an Authorized Distributor of Record for all of the manufacturers it represents.
Contact: Brad Davis
SOURCE BDI Pharma, Inc.